3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Lymphoma
3
Neoplasms
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neoplasm Metastasis
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
38
Radiotherapy
22
Radiosurgery
22
Radiation
11
Magnetic Resonance Spectroscopy
11
Irinotecan
11
Cyclophosphamide
11
Etoposide
10
Surgical Procedures, Operative
9
Erlotinib Hydrochloride
9
Carmustine
9
pembrolizumab
8
Filgrastim
8
Carboplatin
8
Bevacizumab
7
Vincristine
6
Sorafenib
6
O(6)-benzylguanine
6
Nivolumab
6
Flucytosine
6
Aminolevulinic Acid
6
temsirolimus
5
sargramostim
5
Vorinostat
5
Trastuzumab
5
Topotecan
5
Lomustine
5
Imatinib Mesylate
5
Granulocyte Colony-Stimulating Factor
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Brain Neoplasms
×
RRx-001
×
Clear all
NCT04525014
2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1
Terminated
2 enrolled
NCT02215512
2021-11-03
BRAINSTORM
EpicentRx, Inc.
Phase 1
Completed
29 enrolled